Efficacy of a Eugenol-based Product to Improve the Quality of Toothbrushing and Relieving Gum Discomfort Areas

NCT ID: NCT06366568

Last Updated: 2024-04-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-19

Study Completion Date

2024-03-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the efficacy of a eugenol-based product in improving the quality of toothbrushing and relieving areas of gingival discomfort. This is a randomized, controlled, parallel, examiner-blind clinical trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque, Dental

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

toothpaste and gum product, brushing 2x a day for 2 minutes followed by gum product application

Group Type EXPERIMENTAL

fluoride toothpaste containing 1450 ppm of MFP in a PCC base and eugenol gum product

Intervention Type DRUG

PARTICIPANTS WILL USE A EUGENOL BASED product PRIOR TO TOOTHBRUSHING

Group 2

toothpaste , brushing 2x a day for 2 minutes

Group Type PLACEBO_COMPARATOR

fluoride toothpaste containing 1450 ppm of MFP in a PCC base

Intervention Type DRUG

toothbrushing 2x a day for 2 minutes each time

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fluoride toothpaste containing 1450 ppm of MFP in a PCC base and eugenol gum product

PARTICIPANTS WILL USE A EUGENOL BASED product PRIOR TO TOOTHBRUSHING

Intervention Type DRUG

fluoride toothpaste containing 1450 ppm of MFP in a PCC base

toothbrushing 2x a day for 2 minutes each time

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* You must provide consent to participate by signing this informed consent form.
* Available for the two(2) week study duration.
* You must be at least eighteen(18) years old and not older than seventy(70) years of age.
* You must not smoke.
* You must be in good general health for participation in the study, based on the opinion of the study investigator.
* You must have at least 20 natural permanent teeth.
* Your teeth must meet the scoring entry criteria for dental plaque and gingivitis(gum inflammation) at the discretion of the study examiner.
* You must meet the scoring criteria for gum discomfort, determined using your responses to the survey questionnaire.
* You must have no known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredients in the test products as determined by the study examiner.

Exclusion Criteria

* Medical condition which requires premedication prior to dental visits/procedures.
* Presence of fix/ removable prosthodontics dentures that may interfere with this study clinical examinations.
* Advanced periodontal disease (gum disease) and/or treatment for periodontal disease (including surgery) within the past twelve months.
* Five (5) or more decayed, untreated dental sites (cavities) and/or any dental condition requiring urgent dental care.

Abnormalities/diseases of the soft or hard oral tissues.

* Orthodontic appliances/bands/lingual bars that interfere with any clinical assessment (plaque scoring)
* Current smokers and/or tobacco users and/or a history of alcohol or drug abuse.
* Use of drugs that can affect salivary flow.
* Use of antibiotics one (1) month prior to study entry and/or during participation in this study.
* Use of any over the counter medications other than analgesics that could interfere with the study at PI discretion.
* Self-reported pregnancy and/or breastfeeding.
* Current Participation in another clinical study or during the month prior to this clinical study entry.
* Known allergies and/or reactions to common dentifrice ingredients.
* Medical condition which prohibits not eating/drinking or chewing gum for four (4) hours prior to your scheduled visits.
* Immunocompromised conditions (AIDS, immunosuppressive drug therapy).
* Infectious disease and/or other blood borne diseases (Hepatitis series, HIV, tuberculosis).
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Colgate Palmolive

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universitätsklinikum Carl Gustav Carus Technische Universität Dresden Department of Periodontology Fetscherstras

Dresden, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRO-2022-10-PG-MER-MW-JG

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.